Keywords
How to Cite
Abstract
Heart failure is a debilitating chronic condition affecting millions of people worldwide, characterized by the heart's inability to pump blood effectively to meet the body's needs. Over the years, significant advancements have been made in the development of innovative therapies to address this complex condition.
These emerging therapies represent a new hope for patients facing challenges with conventional treatment options or who do not adequately respond to them. Among the most promising advancements are more specific and effective drug therapies, advanced medical devices, and even gene therapy aimed at correcting underlying genetic defects associated with heart failure.
However, with the multitude of therapeutic options available, there is an urgent need for careful assessment to determine the best approach for each patient. This involves considering a range of factors such as the severity of the condition, existing comorbidities, patient tolerability to treatments, and individual preferences.
Furthermore, closely monitoring patient outcomes throughout treatment is crucial. This includes monitoring adherence to therapy, managing potential side effects, and continuously evaluating the effectiveness of the intervention, adjusting the treatment plan as needed to optimize outcomes.
Treatment personalization plays a critical role in this process. Each patient is unique, and the most effective therapeutic approach can vary significantly based on individual characteristics, medical history, and patient preferences. Therefore, healthcare professionals should adopt a patient-centered approach, working closely with patients to develop a personalized treatment plan that takes all these aspects into account.
In summary, advancements in heart failure treatment offer new therapeutic perspectives, but a careful, multidisciplinary, and personalized approach is essential to ensure that patients receive the best possible care and achieve improved quality of life.
References
Antonopoulos, M. et al. "Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices." J. Cardiovasc. Dev. Dis., 2024, 11, 61.
Devadoss, R. et al. "Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment." J. Cardiovasc. Dev. Dis., 2024, 11, 15.
Elendu, C. et al. "A comprehensive review of heart failure: Unraveling the etiology, decoding pathophysiological mechanisms, navigating diagnostic modalities, exploring pharmacological interventions, advocating lifestyle modifications, and charting the horizon of emerging therapies in the complex landscape of chronic cardiac dysfunction." Medicine, 2024, 103:3.
Lyle, M. A. et al. "Circulating Neprilysin in Patients with Heart Failure with Preserved Ejection Fraction." JACC Heart Fail., 2020, 8(1), 70–80.
Patel, P. H. et al. "Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management." Cureus, 13(1), e12419, 2021.
Sapna, FNU et al. "Advancements in Heart Failure Management: A Comprehensive Narrative Review of Emerging Therapies." Cureus, 15(10), e46486, 2023.
Tseng, A. S. et al. "Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis." Circ Arrhythm Electrophysiol., 2019;12:e006951.
Wang, Y. et al. "Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis." European Journal of Medical Research, 2022, 27:314.
Xia, W. et al. "Exploring the therapeutic potential of tetrahydrobiopterin for heart failure with preserved ejection fraction: A path forward." Life Sciences, 345 (2024), 122594.
Zhou, S. et al. "Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future." Front. Cardiovasc. Med., 11:1337154, 2024.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Antônio Angelo Zanon Junior , Luísa Wagner Borges Caldas, Júlia Celga Colnago, Rafael Nunes Catão, Brenda Vitória Macedo Carnero Campoverde